Dulaglutide

Trulicity

Dulaglutide (Trulicity) is a metabolic & fat loss research compound. Long-acting GLP-1 agonist fused to an antibody fragment for a weekly half-life.

How Dulaglutide works

Long-acting GLP-1 agonist fused to an antibody fragment for a weekly half-life.

Proposed benefits

Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.

Can you actually get Dulaglutide?

The evidence for Dulaglutide

Graded by what exists behind each claim.

✅ Clinically validated

• FDA-approved as Trulicity for type 2 diabetes on the AWARD trial program, showing HbA1c reduction with modest weight loss.
• REWIND (9,901 patients, 5.4 years) is the standout: it reduced major adverse cardiovascular events, and unusually most participants did not have established cardiovascular disease at entry — making it the strongest primary-prevention evidence in the class.

📊 Correlative data

• Widely prescribed, weekly dosing, and reported as one of the better-tolerated agonists. Weight loss is real but smaller than semaglutide or tirzepatide, which is why it is rarely the choice when weight is the goal.

🧪 Theoretical / extrapolated

• GLP-1 fused to a modified IgG4 Fc fragment, which gives it a half-life of around five days by recycling through the neonatal Fc receptor — a completely different persistence strategy from liraglutide's albumin binding.
• The large molecular size limits CNS penetration, which is a plausible explanation for why its appetite effect is weaker than semaglutide's despite comparable glycemic control. Size is the trade-off for duration here.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Dulaglutide actually does

In a catalog full of duals and triples, dulaglutide is the single-receptor control: GLP-1 receptor only, no GIP, no glucagon, no amylin. What makes it worth a deep page is not the receptor, which is the best-characterized target in metabolic medicine. It is the delivery vehicle, which is unlike anything else on this list.

What the molecule is. Two GLP-1 analog chains, joined by a peptide linker to a modified human IgG4 Fc fragment — a covalent fusion protein of roughly 63 kDa. Every other weekly agent in this cohort is a small peptide with a fatty acid hung off it that borrows albumin as a carrier Muller 2022. Dulaglutide does not borrow a carrier. It is one.

Consequence one, which is why it lasts. The glomerulus stops filtering proteins somewhere around 60–70 kDa. At 63 kDa this molecule sits at or above that line, so it is not cleared by the kidney the way a 4 kDa peptide is. On top of that, an IgG Fc engages the neonatal Fc receptor, which is the salvage system that rescues immunoglobulin from lysosomal degradation and recycles it back into circulation — the same mechanism that gives an IgG antibody a three-week half-life. That is the persistence engine, and it is a completely different one from the albumin-binding diacids used by ecnoglutide and eloralintide.

Consequence two, which runs the other way and is the reason nobody picks this for weight. A 63 kDa fusion protein does not move around the body like a 4 kDa peptide. GLP-1’s appetite effect has a substantial central component, and the sites that matter sit in and around circumventricular regions that a small acylated peptide reaches more readily than a large protein. That is the standard explanation for why dulaglutide’s weight effect is modest while its glycemic effect is fully competitive — and it is worth being blunt that it is an explanation, not a measurement. No published human study has compared central nervous system exposure between an Fc-fusion GLP-1 and an acylated one.

The DPP-4 problem, solved at the same residue every drug in this cohort solves it at. Native GLP-1 survives about two minutes in plasma because dipeptidyl peptidase-4 clips the first two residues at the His7–Ala8 bond. Every long-acting analog changes that position: ecnoglutide substitutes valine for alanine at position 8 Guo 2023, and dulaglutide carries a glycine substitution at the same site. One residue, chosen independently by every company in this space, is the difference between two minutes and five days.

The number that shows the ceiling is structural. In AWARD-11, going from 1.5 mg to 4.5 mg — a threefold dose increase — bought an extra 0.24% of HbA1c and an extra 1.6 kg of weight at 36 weeks Frias 2021. Tripling the dose of a drug that is well tolerated at the top dose and getting 1.6 kg is not a dosing problem. It is what a flat dose-response looks like when the limiting factor is not how much drug you give.

Cell, rodent, human — and where it stops

Say the scale first, because it is the only thing on this page that no other compound in the cohort can match: 9,901 participants, 371 sites, 24 countries, median 5.4 years.

The outcome trial. REWIND randomized 9,901 adults with type 2 diabetes and either previous cardiovascular disease or cardiovascular risk factors to weekly dulaglutide 1.5 mg or placebo. Median baseline HbA1c was 7.2% — not a rescue population — and mean age 66.2, with 46.3% women. The primary composite of non-fatal myocardial infarction, non-fatal stroke or cardiovascular death occurred in 594 of 4,949 (12.0%) on dulaglutide against 663 of 4,952 (13.4%) on placebo: hazard ratio 0.88 (95% CI 0.79–0.99), p = 0.026 Gerstein 2019. The trial met its primary endpoint.

And what it did not show, which matters as much. All-cause mortality did not differ — 536 (10.8%) against 592 (12.0%), HR 0.90 (0.80–1.01), p = 0.067 Gerstein 2019. A trial of nearly 10,000 people over five and a half years did not demonstrate a mortality benefit. Anyone quoting REWIND as proof that this drug makes you live longer is quoting a result the trial did not produce.

The class context. Pooled across 8 outcome trials and 60,080 patients, GLP-1 receptor agonists reduced major adverse cardiovascular events by 14% (HR 0.86, 0.80–0.93), all-cause mortality by 12%, heart-failure hospitalization by 11% and a composite kidney outcome by 21%, with no increase in severe hypoglycemia, retinopathy or pancreatic adverse effects, and with no significant heterogeneity by structural homology Sattar 2021. That last clause is the interesting one: exendin-based and human-GLP-1-based agents behaved the same, so the benefit belongs to the receptor rather than to any one molecule’s engineering.

The dose-escalation trial. AWARD-11 randomized 1,842 metformin-treated patients to 1.5, 3.0 or 4.5 mg weekly for 52 weeks, with superiority on HbA1c at 36 weeks as the primary objective. Mean baseline HbA1c 8.6%, BMI 34.2 kg/m2. 4.5 mg was superior: −1.77% against −1.54%, estimated treatment difference −0.24%, p < 0.001 on the treatment-regimen estimand. 3.0 mg was superior on the efficacy estimand (−0.17%, p = 0.003) and not on the treatment-regimen estimand (−0.10%, p = 0.096) Frias 2021. A dose that wins under one prespecified analysis and loses under the other is a dose whose benefit is fragile, and the trial reported both rather than the flattering one.

Weight, in the same trial. At 36 weeks: −3.1 kg at 1.5 mg, −4.0 kg at 3.0 mg, −4.7 kg at 4.5 mg, from a mean baseline weight of 95.7 kg Bonora 2021. That is about 4.9% of body weight at the top dose in people with type 2 diabetes. Absolute weight loss was greater at higher baseline BMI but percentage loss was similar across BMI subgroups, and weight reductions were greater in patients with lower baseline HbA1c.

The two independent head-to-heads, which is how you rank a drug. Dulaglutide 1.5 mg has been used as the active comparator in two other companies’ programs, which makes it the best-placed compound in this cohort for an honest ranking. In mazdutide’s phase 2 diabetes trial, open-label dulaglutide gave −1.35% HbA1c and −2.7% weight over 20 weeks against mazdutide’s −1.41% to −1.67% and up to −7.1% Zhang 2023. In EECOH-2, dulaglutide gave −1.65% HbA1c at week 32 against ecnoglutide’s −1.89% and −1.91%; ecnoglutide 1.2 mg was statistically superior at p = 0.0002 and the trialists themselves called the difference not clinically relevant He 2025. Two programs, two continents, the same answer: dulaglutide holds on glycemia and loses on weight.

The obstacles, and they are honest ones. (1) The weight number is the obstacle. −4.7 kg at 4.5 mg over 36 weeks Bonora 2021 is a fraction of what the duals and triples in this same catalog produce, and the gap is not closed by dosing higher, because 4.5 mg is already the top dose and bought 1.6 kg over 1.5 mg Frias 2021. (2) The outcome trial used 1.5 mg. Every cardiovascular number on this page belongs to a dose one third of the maximum Gerstein 2019, and nobody has run an outcome trial at 4.5 mg. (3) REWIND enrolled people with type 2 diabetes at a mean age of 66.2; none of it is a study of a healthy adult using this for body composition. (4) Comparisons against semaglutide in the published literature are indirect treatment comparisons, not randomized head-to-heads at the top doses of each.

Dulaglutide pharmacokinetics — how much of it actually gets in

The catalog says ~5 days. Here is what has to be true behind that, and it is a different mechanism from every other weekly drug in this cohort.

What clears it — and what does not. At roughly 63 kDa this is a protein, not a peptide, and it sits at the edge of the glomerular size cutoff, so renal filtration is not the main clearance route. What removes it is catabolism: proteolysis in tissues and by the reticuloendothelial system, the same fate as an immunoglobulin. Working against that, the IgG4 Fc engages the neonatal Fc receptor, which pulls the protein out of the endosome before it reaches the lysosome and returns it to circulation. The half-life is a balance between proteolysis of the peptide arms and FcRn rescue of the Fc — which is why it lands near 5 days rather than at IgG’s three weeks. It is not a cytochrome substrate and it is not a transporter substrate.

Numbers that bound it. Once-weekly dosing held for 52 weeks in AWARD-11 Frias 2021 and for a median of 5.4 years in REWIND Gerstein 2019, at 0.75, 1.5, 3.0 and 4.5 mg. For comparison, the one measured steady-state half-life in this cohort belongs to a small acylated peptide: ecnoglutide at 124 to 138 hours Guo 2023. Two completely different engineering solutions arriving at the same dosing interval is the single most interesting pharmacokinetic fact in this catalog.

The oral barrier, which is more absolute here than for the peptides. Swallowed, a disulfide-linked 63 kDa fusion protein meets gastric acid and pancreatic proteases and is digested to amino acids. There is no transporter for an intact protein of this size across the enterocyte, and hepatic first-pass extraction would remove anything that somehow crossed. Oral bioavailability is effectively zero, there has never been an oral dulaglutide, and unlike GLP-1 peptides — where absorption enhancers get you to roughly 1% and a company can build a product on that — there is no formulation route that makes an Fc fusion orally available at all.

The route, and what it fixes. Every dose ever given is a subcutaneous injection from a fixed-dose pen, once weekly. Subcutaneous administration of a 63 kDa protein is slow: absorption is largely lymphatic rather than capillary, which contributes to the flat concentration profile and is part of why this molecule produces so little peak-related nausea relative to its exposure — nausea was 13.4%, 15.6% and 16.4% at 1.5, 3.0 and 4.5 mg Frias 2021, which is low for the class.

What would have to be true, and how you would know it was not

Six predictions. Three of them argue against the compound, and the last one is a measurement nobody in this space thinks to take.

1. HbA1c and fasting insulin fall, and the size is already known. Expect roughly −1.5% to −1.8% of HbA1c (Hemoglobin A1c) from a baseline near 8.6% at 1.5–4.5 mg by 36 weeks Frias 2021, with Fasting Insulin falling alongside it as weight comes down. Baseline and 12 weeks, then 36. A flat HbA1c at 12 weeks means nothing; a flat one at 36 means the drug is not being delivered.

2. AGAINST: weight will plateau early and low. Tripling the dose bought 1.6 kg Frias 2021 Bonora 2021. Prediction: on 4.5 mg, the weekly weight curve is close to flat after about week 26, and total loss lands near 5% of body weight rather than the double digits people arrive expecting. Weigh weekly, same conditions. If the curve is still falling at week 36, the cause is the diet, not the dose — and that distinction is worth knowing before someone escalates a drug that has nothing left to give.

3. AGAINST: escalating will cost more gut than it buys effect. Nausea 13.4% → 15.6% → 16.4% and vomiting 5.6% → 8.3% → 9.3% across 1.5, 3.0 and 4.5 mg Frias 2021. The absolute increases are small, and that is the point: the ratio of benefit to gastrointestinal cost does not improve with dose, so there is no dose at which this becomes a weight drug.

4. AGAINST: atrial fibrillation will not improve. REWIND’s post hoc analysis found incident atrial arrhythmia in 269 of 4,769 (5.6%, 10.7 per 1,000 person-years) on dulaglutide against 255 of 4,774 (5.3%, 10.5 per 1,000 person-years) on placebo, p = 0.59, with no effect on the composites of arrhythmia with death or with heart failure Raubenheimer 2022. Cardiovascular benefit in this class is specific, not general, and a drug that cuts stroke and myocardial infarction does not touch this.

5. hs-CRP is the cheapest test of the part nobody explains. The class cardiovascular benefit does not track glycemia and holds across structurally unrelated molecules Sattar 2021, which means something other than glucose control is doing the work. hs-CRP (High-Sensitivity C-Reactive Protein) is retested at 3 months on this site and is the most accessible inflammatory read-out there is. It will not prove a mechanism in one person. A falling hs-CRP alongside an unchanged weight would still be the most informative single result an individual could produce on this drug.

6. The prediction nobody makes: erectile function should improve slightly, over years. REWIND’s exploratory analysis handed the standardized IIEF questionnaire to 3,725 of 5,312 male participants at baseline, 2 years, 5 years and study end. Incident moderate or severe erectile dysfunction ran at 21.3 per 100 person-years on dulaglutide against 22.0 on placebo, HR 0.92 (95% CI 0.85–0.99), p = 0.021, with a least-squares mean difference of 0.61 (0.18–1.05, p = 0.006) in the erectile-function subscore Bajaj 2021. Note the size: this is a small effect in a population where 56.5% already had moderate or severe dysfunction at baseline. But the IIEF is free, it takes four minutes, and it is the only endpoint in this entire cohort a person can measure at home with no equipment. Baseline, 6 months, 12 months. Also draw lipase and amylase at baseline and 12 weeks as the class monitoring, noting that pooled across 60,080 patients this class did not increase pancreatic adverse effects Sattar 2021.

What nobody has tested yet

Five experiments. The first is the most consequential unanswered question in the whole GLP-1 field and it would cost a fortune.

1. Nobody has run a cardiovascular outcome trial at 4.5 mg. REWIND established a 12% relative reduction in the primary composite at 1.5 mg over 5.4 years Gerstein 2019. AWARD-11 established that 4.5 mg is meaningfully better on HbA1c and weight, over 52 weeks, against surrogate endpoints Frias 2021. Whether the cardiovascular benefit is dose-dependent is unknown, and the answer would change prescribing for millions of people. No trial is designed to find out.

2. Nobody has measured central nervous system exposure of an Fc-fusion GLP-1 against an acylated one in a human. The size-limits-brain-access story is the standard explanation for why this drug controls glucose as well as its competitors and controls appetite far less well. It is a plausible mechanism that has never been measured in a person, and it is testable with imaging or with cerebrospinal fluid sampling in a small crossover study.

3. Nobody has repeated the erectile-function finding prospectively. It was exploratory, in 70.1% of the male participants of a trial designed for cardiovascular endpoints Bajaj 2021. No GLP-1 receptor agonist has ever been studied with IIEF as a prespecified primary endpoint, in any population, despite diabetes being one of the largest causes of erectile dysfunction in the world.

4. Nobody has published a body-composition arm at 4.5 mg. At −4.7 kg Bonora 2021 the lean-mass question is smaller than for a 15%-weight-loss agent — but a class base rate of over 25% of lost weight coming from fat-free mass Stefanakis 2024 still puts roughly 1.2 kg of it in the fat-free compartment, in a population with a mean age of 57 in AWARD-11 and 66 in REWIND. Nobody has run the DXA.

5. Nobody has compared the two persistence engines head to head. This cohort contains an Fc fusion at roughly 63 kDa and several small acylated peptides riding albumin, all dosed once weekly. Whether the flatter concentration profile of an Fc fusion produces different tolerability, different receptor desensitization or different central penetration than an albumin-bound peptide at matched receptor exposure is unmeasured — and it is the design question underneath every long-acting peptide made in the last fifteen years Muller 2022.

Dulaglutide — its own safety story, not its class's

This page can say things the other six in this cohort cannot, because it has the exposure to say them: 4,949 people took this drug for a median of 5.4 years in one randomized trial Gerstein 2019. Every safety sentence below is anchored to a number rather than to a mechanism.

1. Gastrointestinal events are the dominant risk and they are common. In REWIND, 2,347 of 4,949 (47.4%) on dulaglutide reported a gastrointestinal adverse event during follow-up against 1,687 of 4,952 (34.1%) on placebo, p < 0.0001 Gerstein 2019. Nearly half. The severity distribution is milder than that headline suggests — nausea ran 13.4% to 16.4% and vomiting 5.6% to 9.3% across the dose range in AWARD-11 Frias 2021 — but the incidence is not small and it rises with dose.

2. What the class was specifically shown not to do. Across 8 outcome trials and 60,080 patients there was no increase in severe hypoglycemia, retinopathy, pancreatitis or pancreatic cancer Sattar 2021. That is a stronger negative statement than any other compound in this cohort can make, and it comes from randomized data rather than from an absence of reports.

3. Hypoglycemia when stacked, stated as a mechanism rather than a warning. GLP-1 receptor-driven insulin secretion is glucose-dependent: as glucose falls the stimulus falls with it, which is why monotherapy hypoglycemia is rare. Insulin and sulfonylureas are not glucose-dependent — they act regardless. So dulaglutide does not cause hypoglycemia so much as it uncovers an insulin or sulfonylurea dose that was already too high for the new level of insulin sensitivity. REWIND participants were on their existing antihyperglycemic regimens Gerstein 2019. The practical consequence is that the background agent is what needs adjusting at initiation, and that the risk arrives in the first weeks rather than at steady state.

4. Gallbladder disease, which is a real class effect and applies here with a specific twist. Across 76 randomized trials and 103,371 patients, GLP-1 receptor agonist use was associated with gallbladder or biliary disease at a relative risk of 1.37 (95% CI 1.23–1.52), with cholelithiasis at 1.27, cholecystitis at 1.36, and a much larger signal in weight-loss trials (2.29, 1.64–3.18) than in diabetes trials (1.27). Risk was higher at higher doses (1.56) and with longer duration (1.40) He 2022. The twist for dulaglutide: its weight loss is modest, which puts it in the lower-risk 1.27 stratum — but its use is indefinite by design, and duration was one of the two multipliers that mattered. Right upper quadrant pain that comes on after meals is the symptom, and it is not a gastrointestinal side effect to titrate through.

5. Atrial fibrillation is not improved, and that is worth knowing before somebody buys this for their heart in general. No difference in incident atrial arrhythmia over 5.4 years, p = 0.59 Raubenheimer 2022.

6. The thyroid C-cell contraindication, stated accurately. The label for this class carries a contraindication in medullary thyroid carcinoma and multiple endocrine neoplasia type 2. It comes from rodent C-cell tumors seen with long-acting GLP-1 receptor agonists, and rodent C cells express far more GLP-1 receptor than human ones do. The pooled human data across 60,080 patients found no pancreatic cancer signal and did not report a thyroid one Sattar 2021. Calcitonin is the marker if it is ever relevant, and it is a test for people with a family history of those two conditions, not a screening test for anybody else — a self-ordered calcitonin in a general population generates false alarms far more often than it generates information.

And the risk this drug does not have. There is no glucagon arm and no GIP arm, so the heart-rate rise that dominates the safety discussion for the duals and triples in this same catalog is not part of this molecule’s story in the same way. Choosing dulaglutide is choosing the smallest effect and the smallest and best-characterized risk surface in this cohort, deliberately.

Sources read for this page

• Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019 · PMID 31189511
• Frias JP, et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care 2021 · PMID 33397768
• Bonora E, et al. Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11. Diabetes, Obesity and Metabolism 2021 · PMID 34189841
• Bajaj HS, et al. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes and Endocrinology 2021 · PMID 34153269
• Raubenheimer PJ, et al. Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial. Diabetes, Obesity and Metabolism 2022 · PMID 34984808
• Sattar N, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology 2021 · PMID 34425083
• He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine 2022 · PMID 35344001
• He Y, et al. Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Diabetes and Endocrinology 2025 · PMID 40854315
• Zhang B, et al. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care 2023 · PMID 37943529
• Guo W, et al. Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Molecular Metabolism 2023 · PMID 37364710
• Muller TD, et al. Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery 2022 · PMID 34815532
• Stefanakis K, et al. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism 2024 · PMID 39481534

Dulaglutide — safety, predicted from mechanism

Dulaglutide — interference & stacking

Bloodwork to run alongside Dulaglutide

Baseline first, then again at 8–12 weeks.

The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.

Check results you already have → · All 103 markers A–Z

Dulaglutide — frequently asked questions

What Dulaglutide is used for

Dulaglutide appears under 2 goals in the goal router.

Related Metabolic & Fat Loss compounds

← Explore the full Protocol Vault

↑ Back to on this page